Search Results - "van Oort, I M"

Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions by Hendriks, R J, van Oort, I M, Schalken, J A

“…BACKGROUND: The diagnosis of prostate cancer (PCa) is currently based on serum PSA testing and/or abnormal digital rectal examination and histopathologic…”
Get full text

The predictive value of endorectal 3 Tesla multiparametric magnetic resonance imaging for extraprostatic extension in patients with low, intermediate and high risk prostate cancer by Somford, D M, Hamoen, E H, Fütterer, J J, van Basten, J P, Hulsbergen-van de Kaa, C A, Vreuls, W, van Oort, I M, Vergunst, H, Kiemeney, L A, Barentsz, J O, Witjes, J A

“…We determined the positive and negative predictive values of multiparametric magnetic resonance imaging for extraprostatic extension at radical prostatectomy…”
Get more information

Adjustment disorder in cancer patients after treatment: prevalence and acceptance of psychological treatment by Van Beek, F. E., Wijnhoven, L. M. A., Custers, J. A. E., Holtmaat, K., De Rooij, B. H., Horevoorts, N. J. E., Aukema, E. J., Verheul, S., Eerenstein, S. E. J., Strobbe, L., Van Oort, I. M., Vergeer, M. R., Prins, J. B., Verdonck-de Leeuw, I. M., Jansen, F.

“…Purpose To investigate the prevalence of adjustment disorder (AD) among cancer patients and the acceptance of psychological treatment, in relation to…”
Get full text

Role of multidisciplinary team meetings in implementation of chemohormonal therapy in metastatic prostate cancer in daily practice by Creemers, S. G., Van Santvoort, B., van den Berkmortel, F. W. P. J., Kiemeney, L. A., van Oort, I. M., Aben, K. K. H., Hamberg, P.

“…Background The recommended treatment for a subset of patients with metastatic prostate cancer (mPC) changed from androgen deprivation therapy (ADT) to…”
Get full text

The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population by Westgeest, H. M., Kuppen, M. C. P., van den Eertwegh, A. J. M., de Wit, R., Bergman, A. M., van Moorselaar, R. J. A., Coenen, J. L. L. M., van den Bergh, A. C. M., Somford, D. M., Mehra, N., van Oort, I. M., Aben, K. K. H., Gerritsen, W. R., Uyl-de Groot, C. A.

“…Background In 2004 docetaxel was the first life-prolonging drug (LPD) registered for metastatic castration-resistant prostate cancer (mCRPC) patients. Between…”
Get full text

Does the Tertiary Gleason Pattern Influence the PSA Progression-Free Interval after Retropubic Radical Prostatectomy for Organ-Confined Prostate Cancer? by van Oort, I.M., Schout, B.M., Kiemeney, L.A.L.M., Hulsbergen, C.A., Witjes, J.A.

“…The Gleason sum is an important prognostic parameter for patients treated with radical prostatectomy for localized prostate cancer. However, frequently more…”
Get full text

A single institution experience with biochemical recurrence after radical prostatectomy for tumors that on pathology are of small volume or “insignificant” by van Oort, I.M., M.D, Kok, Dieuwertje E.G., M.Sc, Kiemeney, Lambertus A., Ph.D, Hulsbergen-van de Kaa, Christina A., M.D., Ph.D, Witjes, J. Alfred, M.D., Ph.D

“…Abstract Objective Small volume prostate cancers (<0.5 cc, svPC), and insignificant prostate cancers (<0.5 cc and Gleason scores <7, InsigPC) are considered…”
Get full text

Urinary incontinence and erectile dysfunction in patients with localized or locally advanced prostate cancer: A nationwide observational study by Vernooij, R.W.M., Cremers, R.G.H.M., Jansen, H., Somford, D.M., Kiemeney, L.A., van Andel, G., Wijsman, B.P., Busstra, M.B., van Moorselaar, R.J.A., Wijnen, E.M., Pos, F.J., Hulshof, M.C.C.M., Hamberg, P., van den Berkmortel, F., Hulsbergen-van de Kaa, C.A., van Leenders, G.J.L.H., Fütterer, J.J., van Oort, I.M., Aben, K.K.H.

“…•Population-based studies on functional outcomes after prostate cancer treatment are scarce.•15% of prostatectomy patients reported urinary incontinence 24…”
Get full text

Quality of life after prostate cancer treatments in patients comparable at baseline by van Tol-Geerdink, J J, Leer, J W H, van Oort, I M, van Lin, E J N T, Weijerman, P C, Vergunst, H, Witjes, J A, Stalmeier, P F M

“…Background: Previous studies on the effects of different prostate cancer treatments on quality of life, were confounded because patients were not comparable…”
Get full text

68Ga-PSMA-PET/CT and Diffusion MRI Targeting for Cone-Beam CT-Guided Bone Biopsies of Castration-Resistant Prostate Cancer Patients by van Steenbergen, T. R. F., Smits, M., Scheenen, T. W. J., van Oort, I. M., Nagarajah, J., Rovers, M. M., Mehra, N., Fütterer, J. J.

“…Introduction Precision medicine expands the treatment options for metastatic castration-resistant prostate cancer (mCRPC) by targeting druggable genetic…”
Get full text

Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223 by van der Doelen, Maarten J., Stockhaus, Agnes, Ma, Yuanjun, Mehra, Niven, Yachnin, Jeffrey, Gerritsen, Winald R., Nilsson, Sten, van Oort, Inge M., Ullén, Anders

“…Purpose Radium-223 is a life-prolonging therapy for castration-resistant prostate cancer (CRPC) patients with symptomatic bone metastases. However, validated…”
Get full text

Maximum tumor diameter is not an independent prognostic factor in high-risk localized prostate cancer by Oort, I.M. van, Witjes, J.A, Kok, D.E.G, Kiemeney, L.A, Hulsbergen-van de Kaa, C.A

“…Objectives Previous studies suggest that maximum tumor diameter (MTD) is a predictor of recurrence in prostate cancer (PC). This study investigates the…”
Get full text

Prognostic effect of neuroendocrine differentiation in prostate cancer: A critical review by Surcel, Cristian I., M.D., Ph.D, van Oort, Inge M., M.D., Ph.D, Sooriakumaran, Prasanna, M.D., Ph.D, Briganti, Alberto, M.D., Ph.D, De Visschere, Peter J.L., M.D, Fütterer, Jurgen J., M.D, Ghadjar, Pirus, M.D., Ph.D, Isbarn, Hendrik, M.D., Ph.D, Ost, Piet, M.D., Ph.D, van den Bergh, Roderick C.N., M.D., Ph.D, Yossepowitch, Ofer, M.D., Ph.D, Giannarini, Gianluca, M.D, Ploussard, Guillaume, MD, PhD

“…Abstract Background The multiple pathways that are involved in neuroendocrine differentiation (NED) in prostate cancer (PCa) are poorly elucidated. Evidence…”
Get full text

The prognostic value of E-cadherin and the cadherin-associated molecules α-, β-, γ-catenin and p120ctn in prostate cancer specific survival: A long-term follow-up study by van Oort, I.M., Tomita, K., van Bokhoven, A., Bussemakers, M.J.G., Kiemeney, L.A., Karthaus, H.F.M., Witjes, J.A., Schalken, J.A.

“…OBJECTIVES To determine the value of loss of expression of E‐cadherin and cadherin associated molecules as prognostic markers for prostate cancer patients in a…”
Get full text

Anterior Cruciate Ligament Rehabilitation for the 10- to 18-Year-Old Adolescent Athlete: Practice Guidelines Based on International Delphi Consensus by van Melick, Nicky, Dietvorst, Martijn, van Oort, Maaike I.A.M., Claessens, Remco L.A., Janssen, Rob P.A., Bogie, Rob, Claussen, William, Greenberg, Elliot M., Grindem, Hege, Kearney, Sharon, van Keulen, Matthijs, Lips, Martijn, Macrina, Lenny, McWilliam, David, Moksnes, Håvard, Norris, Richard, Paterno, Mark V., Picot, Brice, Piskulic, David, Prato, Luis F., Sayer, Timothy A., Sethi, Faraz, Silvers-Granelli, Holly, Truong, Linda, Whalan, Matthew, Witvrouw, Erik

“…Background: There are 2 treatment options for adolescent athletes with anterior cruciate ligament (ACL) injuries—rehabilitation alone (nonsurgical treatment)…”
Get full text

Corrigendum to “Urinary incontinence and erectile dysfunction in patients with localized or locally advanced prostate cancer: A nationwide observational study” by Vernooij, R.W.M., Cremers, R.G.H.M., Jansen, H., Somford, D.M., Kiemeney, L.A., van Andel, G., Wijsman, B.P., Busstra, M.B., van Moorselaar, R.J.A., Wijnen, E.M., Pos, F.J., Hulshof, M.C.C.M., Hamberg, P., van den Berkmortel, F., Hulsbergen-van de Kaa, C.A., van Leenders, G.J.L.H., Fütterer, J.J., van Oort, I.M., Aben, K.K.H.

Get full text

68 Ga-PSMA-PET/CT and Diffusion MRI Targeting for Cone-Beam CT-Guided Bone Biopsies of Castration-Resistant Prostate Cancer Patients by van Steenbergen, T R F, Smits, M, Scheenen, T W J, van Oort, I M, Nagarajah, J, Rovers, M M, Mehra, N, Fütterer, J J

“…Precision medicine expands the treatment options for metastatic castration-resistant prostate cancer (mCRPC) by targeting druggable genetic aberrations…”
Get full text

The Combination of Enzalutamide and Opioids: A Painful Pitfall? by Benoist, Guillemette E., van Oort, Inge M., Burger, David M., Koch, Birgit C.P., Mehra, Niven, van Erp, Nielka P.

Get full text

POSC399 Treatment Effect and Costs of the Complete Therapeutic Pathway in Patients with First-Line Castration-Resistant Prostate Cancer with Either First-Line Docetaxel or Abiraterone Acetate Plus Prednisone by Holleman, MS, Santi, I, Huygens, S, Aben, KKH, Van den Bergh, ACM, Bergman, AM, van den Eertwegh, AJM, Kuppen, MCP, Lavalaye, J, Mehra, NM, van Moorselaar, RJA, Van Oort, IM, Somford, DM, Westgeest, HM, Gerritsen, WR, Uyl-De Groot, CA

Get full text

De dilemma’s van de nieuwe behandelmogelijkheden voor castratieresistent prostaatcarcinoom (CRPC); een filosofische kijk op de toekomst by van Oort, I. M.

“…Samenvatting Het afgelopen jaar is gebleken dat een aantal nieuwe middelen, met verschillende werkingsmechanismen, effectief is. De U.S. Food and Drug…”
Get full text